Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (471-480 of 910) with videos related to

Pageof 91
Sort By:
Circulation|March 13, 2020
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney DiseaseJohn W Stanifer, Sean D Pokorney, Glenn M Chertow, et al.
Indian Heart Journal|April 13, 2017
Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countriesSameer Mehta, Christopher B Granger, Timothy D Henry, et al.
European Heart Journal|November 16, 2022
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillationZiad Hijazi, Alexander P Benz, Johan Lindbäck, et al.
European Heart Journal|June 9, 2009
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trialRenato D Lopes, Laine E Elliott, Harvey D White, et al.
European Journal of Preventive Cardiology|November 27, 2024
Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trialKonstantin A Krychtiuk, Guillaume Marquis-Gravel, Shannon Murphy, et al.
Circulation|January 1, 2013
The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment timesEmil L Fosbol, Christopher B Granger, James G Jollis, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation|June 6, 2012
Expansion of a regional ST-segment-elevation myocardial infarction system to an entire stateJames G Jollis, Hussein R Al-Khalidi, Lisa Monk, et al.
Journal of the American Heart Association|January 12, 2021
Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular DiseaseAdam J Nelson, Maddalena Ardissino, Kevin Haynes, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 18, 2023
Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillationAlexander P Benz, Ziad Hijazi, Johan Lindbäck, et al.
Pageof 91

Showing results (471-480 of 910) with videos related to

Sort By:
Pageof 91
Circulation|March 13, 2020
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney DiseaseJohn W Stanifer, Sean D Pokorney, Glenn M Chertow, et al.
Indian Heart Journal|April 13, 2017
Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countriesSameer Mehta, Christopher B Granger, Timothy D Henry, et al.
European Heart Journal|November 16, 2022
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillationZiad Hijazi, Alexander P Benz, Johan Lindbäck, et al.
European Heart Journal|June 9, 2009
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trialRenato D Lopes, Laine E Elliott, Harvey D White, et al.
European Journal of Preventive Cardiology|November 27, 2024
Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trialKonstantin A Krychtiuk, Guillaume Marquis-Gravel, Shannon Murphy, et al.
Circulation|January 1, 2013
The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment timesEmil L Fosbol, Christopher B Granger, James G Jollis, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation|June 6, 2012
Expansion of a regional ST-segment-elevation myocardial infarction system to an entire stateJames G Jollis, Hussein R Al-Khalidi, Lisa Monk, et al.
Journal of the American Heart Association|January 12, 2021
Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular DiseaseAdam J Nelson, Maddalena Ardissino, Kevin Haynes, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 18, 2023
Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillationAlexander P Benz, Ziad Hijazi, Johan Lindbäck, et al.
Pageof 91